| ID | 116353 |
| Author |
Bando, Hiroshi
Tokushima University|Japan Low Carbohydrate Diet Promotion Association
KAKEN Search Researchers
|
| Keywords | Obesity
Liraglutide
Semaglutide
Glucagon like peptide-1receptor agonists (GLP-1RAs)
Glucose-dependent insulinotropic polypeptide (GIP)
|
| Content Type |
Journal Article
|
| Description | Obesity has been crucial diseases. Several agents have been used including Phentermine, Mazindol, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion and Liraglutide from 1959 to present. Glucagon like peptide-1receptor agonists (GLP-1RAs) has been used for type 2 diabetes mellitus (T2DM). As GLP-1RA, liraglutide is given 0.9 mg/day for T2DM, and 3.0 mg/day for obesity. Similary, semaglutide is given 1.0 mg/week for T2DM and 2.4 mg/week for obesity. Semaglutide brought 14.9% weight reduction for 68 weeks. There is a novel combination of GLP-1RA and glucose-dependent insulinotropic polypeptide (GIP) for treating obesity, which achieved at least 10% weight reduction in 6-39% of cases for 26 weeks.
|
| Journal Title |
Journal of Diabetes, Obesity & Metabolism
|
| Publisher | Yumed Text
|
| Volume | 4
|
| Issue | 2
|
| Start Page | e107
|
| Published Date | 2021-08-09
|
| Rights | Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License(https://creativecommons.org/licenses/by-nc-sa/4.0/).
|
| URL ( Publisher's Version ) | |
| FullText File | |
| language |
eng
|
| TextVersion |
Publisher
|
| departments |
Medical Sciences
|
